cefuroxime axetil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	566	64544-07-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefuroxime axetil cefazine altacef ceftin cefurax oraxim	Molecular weight: 510.47 Formula: C20H22N4O10S CLOGP: 0.90 LIPINSKI: 2 HAC: 14 HDO: 2 TPSA: 189.06 ALOGS: -3.54 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefuroxime axetil
cefazine
altacef
ceftin
cefurax
oraxim

Molecular weight: 510.47
Formula: C20H22N4O10S
CLOGP: 0.90
LIPINSKI: 2
HAC: 14
HDO: 2
TPSA: 189.06
ALOGS: -3.54
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1987	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	134.92	19.00	157	5938	310530	63172397
Oesophageal spasm	99.39	19.00	28	6067	3095	63479832
Nicotine dependence	99.24	19.00	21	6074	696	63482231
Oesophageal pain	99.08	19.00	29	6066	3672	63479255
Sputum purulent	90.54	19.00	21	6074	1066	63481861
Secondary immunodeficiency	85.51	19.00	21	6074	1362	63481565
Trimethylaminuria	73.65	19.00	13	6082	160	63482767
Anaphylactic reaction	70.32	19.00	55	6040	66045	63416882
Lymphoedema	69.76	19.00	30	6065	11662	63471265
Anaphylactic shock	65.88	19.00	36	6059	23597	63459330
Angioedema	57.79	19.00	43	6052	47922	63435005
Urticaria	57.46	19.00	75	6020	165727	63317200
Swollen tongue	53.01	19.00	36	6059	34764	63448163
Full blood count abnormal	51.16	19.00	34	6061	31683	63451244
Dysphonia	49.28	19.00	39	6056	47575	63435352
Swelling face	49.20	19.00	44	6051	63431	63419496
Pseudomembranous colitis	48.01	19.00	16	6079	3096	63479831
Sleep apnoea syndrome	46.43	19.00	31	6064	29102	63453825
Hypersensitivity	43.19	19.00	90	6005	292595	63190332
Megacolon	42.56	19.00	13	6082	1902	63481025
Drug ineffective for unapproved indication	42.06	19.00	31	6064	34032	63448895
Obstructive airways disorder	40.34	19.00	25	6070	20674	63462253
Tinnitus	38.62	19.00	30	6065	35598	63447329
Agitation	37.79	19.00	37	6058	59720	63423207
Dysbiosis	37.54	19.00	10	6085	896	63482031
Pruritus	34.67	19.00	94	6001	361359	63121568
Fluid retention	32.34	19.00	34	6061	59652	63423275
Hallucination	31.09	19.00	32	6063	54785	63428142
Bronchitis	30.67	19.00	48	6047	124887	63358040
Serous retinal detachment	30.08	19.00	7	6088	360	63482567
Product preparation issue	29.42	19.00	9	6086	1323	63481604
Cystitis	29.21	19.00	31	6064	54960	63427967
Cross sensitivity reaction	28.97	19.00	10	6085	2152	63480775
Rash	28.77	19.00	118	5977	560753	62922174
Macular oedema	26.63	19.00	11	6084	3866	63479061
Abdominal pain	25.81	19.00	74	6021	293382	63189545
Anterior chamber inflammation	25.55	19.00	6	6089	321	63482606
Fibromyalgia	24.18	19.00	34	6061	80386	63402541
Clostridium difficile infection	23.68	19.00	21	6074	29901	63453026
Kounis syndrome	23.17	19.00	8	6087	1722	63481205
Hyperhidrosis	23.15	19.00	39	6056	107797	63375130
Abdominal pain upper	22.10	19.00	56	6039	206388	63276539
Joint swelling	21.47	19.00	3	6092	327663	63155264
Breath odour	21.21	19.00	7	6088	1313	63481614
Drug intolerance	20.82	19.00	71	6024	308590	63174337
Migraine	20.38	19.00	36	6059	103310	63379617
Oral discomfort	20.20	19.00	12	6083	9189	63473738
Macular detachment	19.98	19.00	4	6091	100	63482827
Intestinal perforation	19.71	19.00	13	6082	11950	63470977
Retinoschisis	19.38	19.00	3	6092	15	63482912
Inhibitory drug interaction	19.29	19.00	8	6087	2841	63480086
Dermatitis allergic	19.17	19.00	14	6081	15134	63467793

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product preparation issue	76.66	20.83	15	2783	403	34953730
Macular detachment	60.29	20.83	10	2788	101	34954032
Retinal toxicity	46.54	20.83	10	2788	430	34953703
Anterior chamber inflammation	44.62	20.83	9	2789	283	34953850
Pulmonary vasculitis	43.47	20.83	10	2788	589	34953544
Kounis syndrome	41.40	20.83	13	2785	2505	34951628
Macular oedema	39.53	20.83	13	2785	2901	34951232
Neuritis	39.05	20.83	10	2788	924	34953209
Respiratory symptom	36.87	20.83	11	2787	1786	34952347
Retinoschisis	35.77	20.83	5	2793	13	34954120
Sleep disorder due to a general medical condition	35.61	20.83	14	2784	5207	34948926
Metabolic disorder	31.03	20.83	12	2786	4271	34949862
Spinal muscular atrophy	30.82	20.83	7	2791	389	34953744
Retinal oedema	27.40	20.83	7	2791	641	34953492
Haemolytic uraemic syndrome	26.26	20.83	9	2789	2277	34951856
Anaphylactic reaction	25.63	20.83	21	2777	32280	34921853
Neurological symptom	24.32	20.83	10	2788	4175	34949958
Motor neurone disease	23.91	20.83	6	2792	511	34953622
Pneumococcal sepsis	23.50	20.83	7	2791	1130	34953003
Gastrointestinal ischaemia	23.27	20.83	5	2793	215	34953918
Serous retinal detachment	22.90	20.83	6	2792	606	34953527
Corneal oedema	22.31	20.83	7	2791	1344	34952789
Retinal injury	21.71	20.83	4	2794	77	34954056
Mucosal erosion	20.99	20.83	6	2792	838	34953295

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oesophageal spasm	108.04	18.89	31	8143	3425	79732789
Oesophageal pain	105.78	18.89	32	8142	4247	79731967
Anaphylactic reaction	87.83	18.89	71	8103	83672	79652542
Sputum purulent	84.65	18.89	21	8153	1328	79734886
Nicotine dependence	81.22	18.89	19	8155	936	79735278
Drug hypersensitivity	77.73	18.89	122	8052	298794	79437420
Trimethylaminuria	77.68	18.89	14	8160	182	79736032
Lymphoedema	69.31	18.89	31	8143	12382	79723832
Macular detachment	69.27	18.89	13	8161	214	79736000
Anaphylactic shock	68.85	18.89	44	8130	35952	79700262
Anterior chamber inflammation	68.19	18.89	15	8159	559	79735655
Macular oedema	66.74	18.89	24	8150	5450	79730764
Product preparation issue	64.21	18.89	17	8157	1393	79734821
Kounis syndrome	60.69	18.89	21	8153	4261	79731953
Urticaria	60.17	18.89	84	8090	185117	79551097
Secondary immunodeficiency	58.28	18.89	19	8155	3215	79732999
Serous retinal detachment	54.49	18.89	14	8160	1020	79735194
Obstructive airways disorder	54.15	18.89	36	8138	31423	79704791
Retinoschisis	51.86	18.89	8	8166	36	79736178
Angioedema	48.98	18.89	49	8125	75986	79660228
Pseudomembranous colitis	48.85	18.89	19	8155	5355	79730859
Sleep apnoea syndrome	44.85	18.89	34	8140	36444	79699770
Full blood count abnormal	43.85	18.89	35	8139	40439	79695775
Pruritus	42.83	18.89	112	8062	394536	79341678
Corneal oedema	41.63	18.89	14	8160	2606	79733608
Hypersensitivity	41.11	18.89	86	8088	262153	79474061
Retinal infarction	39.52	18.89	8	8166	198	79736016
Rash	39.13	18.89	139	8035	578219	79157995
Tinnitus	39.02	18.89	34	8140	44299	79691915
Pulmonary vasculitis	38.62	18.89	10	8164	751	79735463
Dysbiosis	38.39	18.89	11	8163	1208	79735006
Swollen tongue	38.18	18.89	33	8141	42537	79693677
Megacolon	37.69	18.89	14	8160	3481	79732733
Retinal toxicity	36.80	18.89	11	8163	1400	79734814
Retinal oedema	36.27	18.89	10	8164	955	79735259
Cystitis	35.84	18.89	35	8139	52697	79683517
Dysphonia	35.43	18.89	36	8138	56836	79679378
Swelling face	33.72	18.89	39	8135	71173	79665041
Drug ineffective for unapproved indication	31.12	18.89	32	8142	51206	79685008
Neuritis	30.35	18.89	10	8164	1748	79734466
Bronchitis	29.34	18.89	50	8124	130594	79605620
Cystoid macular oedema	29.18	18.89	10	8164	1970	79734244
Spinal muscular atrophy	28.97	18.89	7	8167	396	79735818
Ocular toxicity	27.97	18.89	8	8166	873	79735341
Fluid retention	27.76	18.89	35	8139	69774	79666440
Fibromyalgia	26.77	18.89	33	8141	64307	79671907
Hallucination	26.48	18.89	38	8136	85707	79650507
Cross sensitivity reaction	26.39	18.89	11	8163	3701	79732513
Agitation	26.23	18.89	41	8133	99674	79636540
Migraine	25.89	18.89	38	8136	87455	79648759
Maculopathy	25.72	18.89	10	8164	2815	79733399
Wheezing	25.34	18.89	44	8130	116620	79619594
Rash maculo-papular	23.72	18.89	29	8145	56049	79680165
Respiratory symptom	23.70	18.89	11	8163	4780	79731434
Clostridium difficile infection	22.97	18.89	25	8149	42660	79693554
Breath odour	22.81	18.89	8	8166	1688	79734526
Motor neurone disease	21.47	18.89	6	8168	602	79735612
Vomiting	20.97	18.89	128	8046	665700	79070514
Toxic epidermal necrolysis	20.40	18.89	24	8150	44557	79691657
Product impurity	20	18.89	4	8170	93	79736121
Metabolic disorder	19.51	18.89	12	8162	9158	79727056
Pneumococcal sepsis	19.18	18.89	7	8167	1655	79734559

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Lyme disease	indication	23502006	DOID:11729
Acute gonococcal urethritis	indication	29864006
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Gonorrhea of rectum	indication	42746002
Impetigo	indication	48277006	DOID:8504
Lower respiratory tract infection	indication	50417007
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute maxillary sinusitis	indication	68272006	DOID:2050
Haemophilus influenzae pneumonia	indication	70036007
Acute bacterial sinusitis	indication	75498004
Escherichia coli urinary tract infection	indication	301011002
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infection due to Staphylococcus aureus	indication	406602003
Acute exacerbation of chronic bronchitis	indication	425748003
Moraxella Catarrhalis Acute Otitis Media	indication	703469002
Streptococcus Pneumoniae Chronic Bronchitis	indication
Haemophilus Parainfluenzae Chronic Bronchitis	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Streptococcus Pneumoniae Bronchitis	indication
Haemophilus Influenzae Bronchitis	indication
Haemophilus Parainfluenzae Bronchitis	indication
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.75	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4017552	VUID
N0000179073	NUI
D00914	KEGG_DRUG
20493	RXNORM
C0055015	UMLSCUI
CHEBI:3516	CHEBI
CHEBI:3515	CHEBI
KOV	PDB_CHEM_ID
CHEMBL1095930	ChEMBL_ID
C040738	MESH_SUPPLEMENTAL_RECORD_UI
Z49QDT0J8Z	UNII
6321416	PUBCHEM_CID
1053	MMSL
4388	MMSL
46962	MMSL
d00056	MMSL
002730	NDDF
003590	NDDF
372833007	SNOMEDCT_US
73986003	SNOMEDCT_US
89678001	SNOMEDCT_US
C0007562	UMLSCUI
DB01112	DRUGBANK_ID
4017552	VANDF
4019668	VANDF
3902	INN_ID
D002444	MESH_DESCRIPTOR_UI
5479529	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CEFUROXIME AXETIL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-215	TABLET, FILM COATED	500 mg	ORAL	ANDA	21 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	16714-400	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	16714-401	TABLET	500 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-150	TABLET	500 mg	ORAL	ANDA	25 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-370	TABLET	250 mg	ORAL	ANDA	25 sections
cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-584	TABLET	250 mg	ORAL	ANDA	23 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-623	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime Axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-623	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-656	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-657	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	50090-0781	TABLET	250 mg	ORAL	ANDA	24 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2157	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2157	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2158	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2158	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2159	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Cefuroxime axetil	Human Prescription Drug Label	1	50090-2159	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Cefuroxime Axetil	Human Prescription Drug Label	1	50090-4153	TABLET	500 mg	ORAL	ANDA	26 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-333	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-333	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-333	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-334	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-334	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
Cefuroxime axetil	HUMAN PRESCRIPTION DRUG LABEL	1	51407-334	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections